(19)
(11)EP 3 320 900 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
13.06.2018 Bulletin 2018/24

(43)Date of publication A2:
16.05.2018 Bulletin 2018/20

(21)Application number: 17203691.5

(22)Date of filing:  24.02.2012
(51)International Patent Classification (IPC): 
A61K 31/282(2006.01)
G01N 33/574(2006.01)
A61K 31/513(2006.01)
A61K 33/24(2006.01)
G01N 33/50(2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 24.03.2011 JP 2011065993

(62)Application number of the earlier application in accordance with Art. 76 EPC:
16180500.7 / 3139172
12759998.3 / 2690442

(71)Applicants:
  • Keio University
    Tokyo 108-8345 (JP)
  • Kabushiki Kaisha Yakult Honsha
    Tokyo 105-8660 (JP)

(72)Inventors:
  • TANIGAWARA, Yusuke
    Tokyo, 160-8582 (JP)
  • NISHIMUTA, Akito
    Tokyo, 160-8582 (JP)
  • OTANI, Yuki
    Tokyo, 160-8582 (JP)
  • MATSUO, Mitsuhisa
    Tokyo, 105-8660 (JP)

(74)Representative: Blodig, Wolfgang 
Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB Weinstrasse 8
80333 München
80333 München (DE)

  


(54)MARKER FOR DETERMINATION OF SENSITIVITY TO ANTICANCER AGENT


(57) The invention provides a marker for determining sensitivity of a subject having cancer to an anti-cancer agent in a biological sample derived from the subject, said marker being one or more selected from cysteine-glutathione and guanosine, and said anti-cancer agent being selected from oxaliplatin, fluorouracil, and a salt thereof. The invention also provides a method for determining sensitivity of a subject having cancer to an anti-cancer agent selected from oxaliplatin, fluorouracil, and a salt thereof, comprising measuring the level of a substances selected from cysteine-glutathione and guanosine in a specimen derived from the subject.





Search report















Search report